Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival ...

Mesothelin-targeted CAR-NKT cells leveraged three recognition mechanisms, potentially limiting antigen escape and immunoediting compared with single-pathway CAR-T constructs. Complete tumor ...

TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...

Immunotherapy. 2011;3(10):1167-1184. Specifically, iNKT cells appear to inhibit early disease progression with their loss facilitating disease progression, while at later inflammatory stages, NKT ...

PALO ALTO, Calif., Jan. 30, 2026 /PRNewswire/ -- Leading GMP cell therapy CDMO I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells ...

UCLA researchers have developed a new kind of immunotherapy that harnesses the body’s immune system to fight cancer more effectively. The innovative cell therapy uses specially engineered immune cells ...

A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to treat multiple solid tumors. The study focused on engineered invariant ...

GRI Bio, Inc., a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, announced that the European Patent Office has ...

Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, Sept. 30, 2024 (GLOBE NEWSWIRE) ...

Phase I clinical trials, using αGalCer-loaded DCs to target iNKT cells, have shown promise in treating some patients with cancer. As humans have a low frequency of iNKT cells, therapies that combine ...